首页 | 本学科首页   官方微博 | 高级检索  
     


Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS
Authors:Samuel S. Engel MD  Shailaja Suryawanshi PhD  Susanna R. Stevens MS  Robert G. Josse MBBS  FRCP   FRCPC  Jan H. Cornel MD  PhD  Neli Jakuboniene MD  PhD  Axel Riefflin MD  Tsvetalina Tankova MD  PhD   DMedSci  Julio Wainstein MD  Eric D. Peterson MD  MPH  Rury R. Holman MB ChB  FRCP   FMedSci
Affiliation:1. Merck & Co., Inc., Kenilworth, New Jersey;2. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina;3. St. Michael's Hospital, University of Toronto, Toronto, Canada;4. Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, the Netherlands;5. Working group on Cardiovascular Research the Netherlands (WCN), Utrecht, the Netherlands;6. Department of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania;7. GMP Husby, Husby, Germany;8. Clinical Center of Endocrinology, Medical University, Sofia, Bulgaria;9. Wolfson Medical Center, Sackler Faculty of Medicine, Tel‐Aviv University, Tel Aviv, Israel;10. Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK
Abstract:
Keywords:chronic kidney disease  diabetes  sitagliptin
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号